Shifting paradigms in the pharmacogenetics of warfarin

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1373-1375

  Gak, Eva ^a,b   Halkin, Hillel ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CHROMOSOME PROTEIN; CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ANTICOAGULATION; BLEEDING; DOSE RESPONSE; DRUG SENSITIVITY; EDITORIAL; ETHNIC DIFFERENCE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; PHARMACOGENETICS; POPULATION GENETICS; RACE DIFFERENCE; THROMBOSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; AMINO ACID SUBSTITUTION; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC MARKERS; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JEWS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POPULATION GROUPS; PRACTICE GUIDELINES AS TOPIC; TYROSINE; WARFARIN;

EID: 55449123115     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1373     Document Type: Editorial

References (29)

1. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
2. Vecsler M, Loebstein R, Almog S et al.: Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-211 (2006).
3. Tham LS, Goh BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
4. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
5. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
6. Schwarz UI, Ritchie MD, Bradford Y et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
7. Wadelius M, Chen LY, Lindh JD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) (Epub ahead of print).
8. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl. 6), S160-S198 (2008).
9. Absher RK, Moore ME, Parker MH: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36, 1512-1517 (2002).
10. Gan GG, Teh A, Goh KY, Chong HT, Pang KW. Racial background is a determinant factor in the maintenance dosage of warfarin. Int. J. Hematol. 78, 84-86 (2003).
11. Dang MT, Hambleton J, Kayser SR: The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother. 39, 1008-1012 (2005).
12. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
13. Geisen C, Watzka M, Sittinger K et al.: VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005).
14. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African-Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
15. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH: Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8, 1535-1544 (2007).
16. Limdi NA, Arnett DK, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008).
17. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
18. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
19. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD: Pharmacodynamic resistance to warfarin associated with a Va166Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb. Haemost. 93, 23-26 (2005).
20. Loebstein R, Vecsler M, Kurnik D et al.: Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77, 365-372 (2005).
21. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109, 2477-2480, (2007).
22. Scott SA, Edelmann L, Kornreich R, Desnick RJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am. J. Hum. Genet. 82, 495-500 (2008).
23. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E: VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111, 3903-3904 (2008).
24. D'Andrea G, D'Ambrosio R, Margaglione M: Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev. 22, 127-140 (2008).
25. Rost S, Fregin A, Hünerberg M, Bevans CG, Müller CR, Oldenburg J: Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structured requirements for enzymatic activity and inhibition by warfarin. Thromb. Haemost. 94, 780-786 (2005).
26. Wallin R, Wajih N, Hutson SM: VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors. Vitam. Horm. 78, 227-246 (2008).
27. Parker AL, Waddington SN, Nicol CG et al.: Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561 (2006).
28. Kakizaki S, Sohara N, Sato K et al.: Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J. Gastroenterol. Hepatol. 22, 518-522 (2007).
29. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).